Preclinical models of angioimmunoblastic T-cell lymphoma for therapeutic investigation
This technology is a murine model of angioimmunoblastic T-cell lymphoma with Rhoa G17V expression, which recapitulates the features of human disease for further study and therapeutic development.
Unmet Need: Translational murine models for the investigation of angioimmunoblastic T-cell lymphoma
The standard of care treatment for angioimmunoblastic T-cell lymphoma (AITL) is a combination of non-specific chemotherapies, which is associated with side effects and toxicity. As such, there is a need to develop more targeted therapies for the treatment of AITL. However, in order to identify new drug therapies, model systems must be developed that have direct translational potential by recapitulating the genetic landscape, transcriptional profile, and pathological phenotype of the disease.
The Technology: RhoA G17V mutant mouse model of AITL
This technology is a murine model of AITL which harbors mutations commonly associated with angioimmunoblastic T-cell lymphoma, in order to better recapitulate the human disease. In the model, conditional expression of RhoA G17V in T-cells alongside Tet2 knockout mirrors the immunophenotypic and transcriptional features of the human disease. An additional murine lymphoma cell line containing the same mutations has also been identified. These models can be used to and can be used for further study of AITL, as well as in vitro drug screening and in vivo experimentation.
Applications:
- Investigational tool for the role of RhoA in AITL
- Research model for the progression of AITL
- Drug screening tool
Advantages:
- Recapitulates the human disease pathology and progression
- Allows for inducible expression of AITL
- Can be used for both in vitro and in vivo studies
Lead Inventor:
Related Publications:
Tech Ventures Reference:
IR CU23322
Licensing Contact: Joan Martinez